Pierre Fabre, a major player in the Asia-Pacific region, has decided to invest billions to improve its performance and achieve further growth objectives. This move is due to the growing importance of Asia in the future prospects of Pierre Fabre, which aims to become a global leader in dermatology and cosmetics. The CEO of Pierre Fabre, Eric Ducournau, emphasized the significance of Asia in the company's growth strategy. 'The region Asia-Pacific is more important for us than America,' he said. 'We are making significant progress in this area.' The company invested approximately €60 million within the framework of a strategic growth project.

This investment primarily refers to the pharmaceutical sector where the company is developing new products and collaborating with biotech partners to find potential drug candidates. Pierre Fabre's strategy is based on two key points: first, investing in research and development to improve its own capabilities and innovation skills; second, international expansion, which includes opening new production sites and extending existing market areas. Additionally, Pierre Fabre has set realistic and conceptual goals for the upcoming years.

The company has planned an increase of its product network from €17 billion to €300 billion, while setting a yearly growth rate of 8% for the entire group. In this project context, Pierre Fabre decided to focus on eastern regions where the company already has a strong presence. Eastern regions are considered as a large opportunity due to their vast and rich population that requires a different approach compared to other parts of the world. CEO of Pierre Fabre emphasized that Asia-Pacific is an important area for the society but it's not just about market issues. 'We are looking to create a new business model that is more efficient and competitive', said Ducournau. Finally, Pierre Fabre noted that the importance of Asia-Pacific can also be seen in its strategic growth policies.

The growth strategy of the company is based on seeking opportunities in the pharmaceutical sector and in the Asia-Pacific region.